MannKind Corporation (MNKD)
NASDAQ: MNKD · IEX Real-Time Price · USD
5.71
-0.01 (-0.17%)
Jul 19, 2024, 4:00 PM EDT - Market closed
MannKind Employees
As of December 31, 2023, MannKind had 414 total employees, including 411 full-time and 3 part-time employees. The number of employees increased by 19 or 4.81% compared to the previous year.
Employees
414
Change (1Y)
19
Growth (1Y)
4.81%
Revenue / Employee
$542,510
Profits / Employee
$20,500
Market Cap
1.55B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Teladoc Health | 5,600 |
Evotec SE | 4,952 |
Schrödinger | 867 |
Alphatec Holdings | 839 |
Supernus Pharmaceuticals | 652 |
Kiniksa Pharmaceuticals | 297 |
Avadel Pharmaceuticals | 154 |
Kura Oncology | 142 |
MNKD News
- 4 weeks ago - INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association's 84th Scientific Sessions - GlobeNewsWire
- 6 weeks ago - Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions - GlobeNewsWire
- 7 weeks ago - Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation - PRNewsWire
- 7 weeks ago - MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix - GlobeNewsWire
- 2 months ago - MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update - GlobeNewsWire
- 2 months ago - MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease - GlobeNewsWire
- 2 months ago - MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024 - GlobeNewsWire
- 2 months ago - MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases - GlobeNewsWire